The investigational transdermal delivery system, known as Xulane Lo, is designed to deliver 150mcg of norelgestromin and 17.5mcg of ethinyl estradiol per day.

The fertility rate in the U.S. was on a constant decline between 2014 and 2020 and has fluctuated since then, CDC reports.